Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$839M |
| 2 |
Amazon
AMZN
|
+$810M |
| 3 |
Tesla
TSLA
|
+$644M |
| 4 |
TSMC
TSM
|
+$546M |
| 5 |
Johnson & Johnson
JNJ
|
+$389M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$891M |
| 2 |
Home Depot
HD
|
+$441M |
| 3 |
JPMorgan Chase
JPM
|
+$335M |
| 4 |
NVO
Novo Nordisk
NVO
|
+$317M |
| 5 |
ASML
ASML
|
+$315M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.84% |
| 2 | Technology | 15.57% |
| 3 | Consumer Discretionary | 11.88% |
| 4 | Consumer Staples | 10.09% |
| 5 | Financials | 9.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CHX
1751
DELISTED
ChampionX
CHX
| $3.32M | ﹤0.01% |
+114,416
| New | +$3.16M |
|
|
MTLS
1752
Materialise
MTLS
$400M
| $3.31M | ﹤0.01% |
376,500
+68,800
| +22% | +$681K |
|
1753
Bankunited
BKU
$3.44B
| $3.31M | ﹤0.01% |
97,300
-21,400
| -18% | -$756K |
|
1754
BlueLinx
BXC
$680M
| $3.3M | ﹤0.01% |
46,400
-1,400
| -3% | -$95.4K |
|
1755
RCI Hospitality Holdings
RICK
$236M
| $3.3M | ﹤0.01% |
35,400
+9,400
| +36% | +$783K |
|
1756
Western Digital
WDC
$175B
| $3.3M | ﹤0.01% |
138,230
-12,700
| -8% | -$335K |
|
|
QVCGA
1757
DELISTED
QVC Group Inc Series A
QVCGA
| $3.29M | ﹤0.01% |
40,347
-10,810
| -21% | -$1.1M |
|
1758
Monarch Casino & Resort
MCRI
$2.22B
| $3.28M | ﹤0.01% |
42,700
+8,100
| +23% | +$612K |
|
1759
Global X Uranium ETF
URA
$6.27B
| $3.27M | ﹤0.01% |
+163,100
| New | +$3.3M |
|
|
VZIO
1760
DELISTED
VIZIO Holding Corp.
VZIO
| $3.27M | ﹤0.01% |
440,800
+27,700
| +7% | +$268K |
|
1761
PDS Biotechnology
PDSB
$12.9M
| $3.27M | ﹤0.01% |
247,337
-74,987
| -23% | -$529K |
|
1762
Valhi
VHI
$459M
| $3.25M | ﹤0.01% |
147,617
-18,370
| -11% | -$446K |
|
1763
Cullinan Oncology
CGEM
$1.31B
| $3.25M | ﹤0.01% |
307,700
+5,505
| +2% | +$66.9K |
|
1764
eHealth
EHTH
$39.1M
| $3.24M | ﹤0.01% |
670,028
+68,028
| +11% | +$254K |
|
1765
MacroGenics
MGNX
$268M
| $3.24M | ﹤0.01% |
483,123
-26,100
| -5% | -$143K |
|
1766
Exponent
EXPO
$3.19B
| $3.24M | ﹤0.01% |
32,700
-31,400
| -49% | -$3.05M |
|
|
WHWK
1767
Whitehawk Therapeutics
WHWK
$254M
| $3.22M | ﹤0.01% |
251,222
+7,300
| +3% | +$95.3K |
|
1768
Mitek Systems
MITK
$877M
| $3.22M | ﹤0.01% |
332,000
-112,200
| -25% | -$1.18M |
|
1769
DT Midstream
DTM
$14B
| $3.21M | ﹤0.01% |
58,100
-65,400
| -53% | -$3.74M |
|
1770
Banner Corp
BANR
$2.52B
| $3.2M | ﹤0.01% |
+50,699
| New | +$3.4M |
|
1771
Quad
QUAD
$513M
| $3.2M | ﹤0.01% |
785,100
-82,600
| -10% | -$263K |
|
1772
LifeVantage
LFVN
$82.9M
| $3.19M | ﹤0.01% |
858,718
-46,400
| -5% | -$177K |
|
1773
Culp Inc
CULP
$41.9M
| $3.19M | ﹤0.01% |
695,617
-35,500
| -5% | -$168K |
|
1774
Lindsay Corp
LNN
$1.17B
| $3.19M | ﹤0.01% |
19,600
-14,700
| -43% | -$2.42M |
|
|
CCC
1775
CCC Intelligent Solutions
CCC
$4.11B
| $3.19M | ﹤0.01% |
366,400
+308,700
| +535% | +$2.75M |
|
Similar funds
Jim Simons's Q4 2022 Portfolio in Review
As of Q4 2022, Jim Simons held 4,601 positions worth $73.1B, up 3.4% from $70.7B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Jim Simons's Q4 2022 filing shows 626 new, 1,390 increased, 2,018 reduced and 524 closed positions. Its largest new stake was Johnson & Johnson: 2,254,125 shares worth $398M. The largest sale was Microsoft, an estimated $891M.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2022 buy was Johnson & Johnson: 2,254,125 shares worth $398M.
- Jim Simons added most to Apple in Q4 2022, an estimated $839M increase.
- Jim Simons's biggest Q4 2022 reduction was Novo Nordisk, cutting an estimated $317M.
- Jim Simons fully exited Microsoft in Q4 2022, selling an estimated $891M.
- Jim Simons's ten largest holdings make up 11% of its $73.1B portfolio in Q4 2022.
- Jim Simons opened 626 new positions and closed 524 in Q4 2022.
- Jim Simons's portfolio value rose 3.4% quarter-over-quarter to $73.1B.
Based on Renaissance Technologies's 13F filing for Q4 2022, filed 13 Feb 2023.